Nomegestrol acetate
Highest phase reached
Approved
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Nomegestrol acetate
- Molecular weight
- 370.49
- Structure (SMILES)
- CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
- ioa
- Ioa
- 17 acetoxy 6 methyl 19 norpregn 4 6 dien 3 20 dione
- 17-ACETOXY-6-METHYL-19-NORPREGN-4,6-DIEN-3,20-DIONE
- 19 norpregna 4 6 diene 3 20 dione 17 acetyloxy 6 methyl
- 19-NORPREGNA-4,6-DIENE-3,20-DIONE, 17-(ACETYLOXY)-6-METHYL-
- 6 methyl 3 20 dioxo 19 norpregna 4 6 dien 17 yl acetate
- 6-Methyl-3,20-dioxo-19-norpregna-4,6-dien-17-yl acetate
- nomac
- Nomac
- NOMAC
- nomegestrol acetate
- Nomegestrol acetate
- NOMEGESTROL ACETATE [EP MONOGRAPH]
- NOMEGESTROL ACETATE [MART.]
- NOMEGESTROL ACETATE [USAN]
- Nomegestrol acetate [WHO-DD]
- nomegestrol acetate ep monograph
- nomegestrol acetate mart
- nomegestrol acetate usan
- nomegestrol acetate who dd
- org 10486 0
- ORG 10486-0
- ORG-10486-0
- tx 066
- TX 066
- TX-066
And 2 more, listed on the interactive page.
- ATC classification codes
- G03DB04
Sources for recorded values
- CAS registry numbers
- 58652-20-3
- ChEMBL ID
- CHEMBL1476022
- InChIKey
- IIVBFTNIGYRNQY-YQLZSBIMSA-N
- PubChem compound IDs
- 91668
- FDA ingredient codes (UNII)
- 83J78V5W05
- 31930
- 53744
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -estr-; -gest-
Mechanisms of action
- Mechanism
- Progesterone receptor agonist
- Action type
- Agonist
- Target
- Progesterone receptor
- Protein identifier
- P06401
Open Targets mechanisms
- Mechanism
- Progesterone receptor agonist
- Action type
- Agonist
- Target
- Progesterone receptor
- Condition
- Polycystic Ovary Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000660
- Subject identifier
- D011085
- Condition
- Menopause
- Highest recorded phase
- 1
- Condition identifier
- GO:0042697
- Subject identifier
- D008593
- Condition
- Dysmenorrhea
- Highest recorded phase
- 2
- Condition identifier
- HP:0100607
- Subject identifier
- D004412
- Condition
- Multiple Sclerosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005301
- Subject identifier
- D009103
- Condition identifier
- EFO_0000660
- Highest recorded phase
- 1
- Condition identifier
- EFO_0009520
- Highest recorded phase
- 4
- Condition identifier
- GO_0030728
- Highest recorded phase
- 2
- Condition identifier
- GO_0042697
- Highest recorded phase
- 1
- Condition identifier
- HP_0100607
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007254
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0008487
- Highest recorded phase
- 1
- Event
- amenorrhoea
- Reports
- 3
- Reporting signal score
- 11.4932
- Event
- dysmenorrhoea
- Reports
- 2
- Reporting signal score
- 8.6086
- Event
- exposure keratitis
- Reports
- 1
- Reporting signal score
- 9.6027
- Event
- hyperprolactinaemia
- Reports
- 2
- Reporting signal score
- 8.77761
- Event
- hypomenorrhoea
- Reports
- 3
- Reporting signal score
- 18.2999
- Event
- meningioma
- Reports
- 3
- Reporting signal score
- 14.8508
- Event
- meningioma surgery
- Reports
- 1
- Reporting signal score
- 8.4241
- Event
- peripheral swelling
- Reports
- 4
- Reporting signal score
- 7.58774
- Event
- pregnancy on oral contraceptive
- Reports
- 2
- Reporting signal score
- 11.1762
- Event
- thrombosis
- Reports
- 6
- Reporting signal score
- 17.2429
- Event
- tracheal pain
- Reports
- 1
- Reporting signal score
- 7.6144
- Event
- xith nerve injury
- Reports
- 1
- Reporting signal score
- 10.2958
- NCT00127075
- NCT01345786
- NCT01603745
- NCT01670656
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 0
- Polar surface area
- 60.44
- Calculated partition coefficient (ALogP)
- 4.19
- Calculated partition coefficient (XLogP)
- 2.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 27
- Molecular formula
- C23H30O4
- Monoisotopic mass
- 370.21440943
- Natural product
- Yes
- Recorded assays
- 608
- Active assays
- 9
- Confirmatory
- Screening
Related records
Trials (20)
- A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)
- A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)
- A Trial to Assess the Pharmacokinetic Profile (e.g., Uptake, Distribution and Excretion of a Substance in the Body) of Nomegestrol Acetate (NOMAC), Estradiol (E2) and Estrone (E1) After Multiple and Single Dose Administration of the Combined Oral Contraception NOMAC-E2 (COMPLETED)(P05822)
- Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)
- Comparison of Coagulation Profiles Between Zoely and Minidoz: RCT
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
- Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome
- Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)
- Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)
- Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)
- Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)
- Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)
- Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)
- Minimal Effective Dose of Nomegestrol Acetate Inhibiting the Ovulation in Women Receiving Estradiol
- Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception
- POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)
- The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation
- The Use of Nomegestrol Acetate/Estradiol in Random Start Rapid Endometrial Preparation
- Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)
In development for (3)
- Dysmenorrhea Phase 2
- Multiple sclerosis Phase 3
- Polycystic ovary syndrome Phase 1
Other linked conditions (1)
Targets (1)
- PGR Progesterone receptor agonist